Hepatitis C VLPs Delivered to Dendritic Cells by a TLR2 Targeting Lipopeptide Results in Enhanced Antibody and Cell-Mediated Responses

PLoS ONE

Volumn 7, Issue 10, 2012, Pages

  Chua, Brendon Y ^a   Johnson, Douglas ^a,b   Tan, Amabel ^a   Earnest Silveira, Linda ^a   Sekiya, Toshiki ^a   Chin, Ruth ^a   Torresi, Joseph ^a,b   Jackson, David C ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b AUSTIN HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM HYDROXIDE; LIPOPEPTIDE; STRUCTURAL PROTEIN; TOLL LIKE RECEPTOR 2;

ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CELL MATURATION; CELLULAR IMMUNITY; DENDRITIC CELL; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; IMMUNOGENICITY; VIRUS LIKE AGENT;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODY FORMATION; CELL LINE; DENDRITIC CELLS; FEMALE; HEPATITIS C; HEPATITIS C ANTIBODIES; HUMANS; IMMUNITY, CELLULAR; LIPOPEPTIDES; MICE; TOLL-LIKE RECEPTOR 2; VACCINES, VIRUS-LIKE PARTICLE; VIRUS INTERNALIZATION;

EID: 84867624038     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0047492     Document Type: Article

References (47)

1. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, et al. (2001) Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358: 958-965.
2. Sarrazin C, Hezode C, Zeuzem S, Pawlotsky JM, (2012) Antiviral strategies in hepatitis C virus infection. Journal of hepatology 56 Suppl 1: S88-100.
3. Lauer GM, Lucas M, Timm J, Ouchi K, Kim AY, et al. (2005) Full-breadth analysis of CD8+ T-cell responses in acute hepatitis C virus infection and early therapy. Journal of virology 79: 12979-12988.
4. Smyk-Pearson S, Tester IA, Lezotte D, Sasaki AW, Lewinsohn DM, et al. (2006) Differential antigenic hierarchy associated with spontaneous recovery from hepatitis C virus infection: implications for vaccine design. The Journal of infectious diseases 194: 454-463.
5. Grebely J, Conway B, Raffa JD, Lai C, Krajden M, et al. (2006) Hepatitis C virus reinfection in injection drug users. Hepatology 44: 1139-1145.
6. Puig M, Mihalik K, Tilton JC, Williams O, Merchlinsky M, et al. (2006) CD4+ immune escape and subsequent T-cell failure following chimpanzee immunization against hepatitis C virus. Hepatology 44: 736-745.
7. Pestka JM, Zeisel MB, Blaser E, Schurmann P, Bartosch B, et al. (2007) Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C. Proceedings of the National Academy of Sciences of the United States of America. 104: 6025-6030.
8. Raghuraman S, Park H, Osburn WO, Winkelstein E, Edlin BR, et al. (2012) Spontaneous clearance of chronic hepatitis C virus infection is associated with appearance of neutralizing antibodies and reversal of T-cell exhaustion. The Journal of infectious diseases 205: 763-771.
9. Nattermann J, Schneiders AM, Leifeld L, Langhans B, Schulz M, et al. (2005) Serum antibodies against the hepatitis C virus E2 protein mediate antibody-dependent cellular cytotoxicity (ADCC). Journal of hepatology 42: 499-504.
10. Grollo L, Torresi J, Drummer H, Zeng W, Williamson N, et al. (2006) Exploiting information inherent in binding sites of virus-specific antibodies: design of an HCV vaccine candidate cross-reactive with multiple genotypes. Antiviral therapy 11: 1005-1014.
11. Tarr AW, Owsianka AM, Timms JM, McClure CP, Brown RJ, et al. (2006) Characterization of the hepatitis C virus E2 epitope defined by the broadly neutralizing monoclonal antibody AP33. Hepatology 43: 592-601.
12. Torresi J, Fischer A, Grollo L, Zeng W, Drummer H, et al. (2007) Induction of neutralizing antibody responses to hepatitis C virus with synthetic peptide constructs incorporating both antibody and T-helper epitopes. Immunology and cell biology 85: 169-173.
13. Law M, Maruyama T, Lewis J, Giang E, Tarr AW, et al. (2008) Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge. Nature medicine 14: 25-27.
14. Krey T, d'Alayer J, Kikuti CM, Saulnier A, Damier-Piolle L, et al. (2010) The disulfide bonds in glycoprotein E2 of hepatitis C virus reveal the tertiary organization of the molecule. PLoS pathogens 6: e1000762.
15. Meunier JC, Russell RS, Goossens V, Priem S, Walter H, et al. (2008) Isolation and characterization of broadly neutralizing human monoclonal antibodies to the e1 glycoprotein of hepatitis C virus. Journal of virology 82: 966-973.
16. Lechmann M, Murata K, Satoi J, Vergalla J, Baumert TF, et al. (2001) Hepatitis C virus-like particles induce virus-specific humoral and cellular immune responses in mice. Hepatology 34: 417-423.
17. Murata K, Lechmann M, Qiao M, Gunji T, Alter HJ, et al. (2003) Immunization with hepatitis C virus-like particles protects mice from recombinant hepatitis C virus-vaccinia infection. Proceedings of the National Academy of Sciences of the United States of America 100: 6753-6758.
18. Steinmann D, Barth H, Gissler B, Schurmann P, Adah MI, et al. (2004) Inhibition of hepatitis C virus-like particle binding to target cells by antiviral antibodies in acute and chronic hepatitis C. Journal of virology. 78: 9030-9040.
19. Barth H, Ulsenheimer A, Pape GR, Diepolder HM, Hoffmann M, et al. (2005) Uptake and presentation of hepatitis C virus-like particles by human dendritic cells. Blood 105: 3605-3614.
20. Choo QL, Kuo G, Ralston R, Weiner A, Chien D, et al. (1994) Vaccination of chimpanzees against infection by the hepatitis C virus. Proceedings of the National Academy of Sciences of the United States of America 91: 1294-1298.
21. Rosa D, Campagnoli S, Moretto C, Guenzi E, Cousens L, et al. (1996) A quantitative test to estimate neutralizing antibodies to the hepatitis C virus: cytofluorimetric assessment of envelope glycoprotein 2 binding to target cells. Proceedings of the National Academy of Sciences of the United States of America 93: 1759-1763.
22. Garrone P, Fluckiger AC, Mangeot PE, Gauthier E, Dupeyrot-Lacas P, et al. (2011) A prime-boost strategy using virus-like particles pseudotyped for HCV proteins triggers broadly neutralizing antibodies in macaques. Science translational medicine 3: 94ra71.
23. Chua BY, Pejoski D, Turner SJ, Zeng W, Jackson DC, (2011) Soluble proteins induce strong CD8+ T cell and antibody responses through electrostatic association with simple cationic or anionic lipopeptides that target TLR2. Journal of immunology 187: 1692-1701.
24. Chin R, Earnest-Silveira L, Koeberlein B, Franz S, Zentgraf H, et al. (2007) Modulation of MAPK pathways and cell cycle by replicating hepatitis B virus: factors contributing to hepatocarcinogenesis. Journal of hepatology 47: 325-337.
25. Zeng W, Jackson DC, Rose K, (1996) Synthesis of a new template with a built-in adjuvant and its use in constructing peptide vaccine candidates through polyoxime chemistry. Journal of peptide science: an official publication of the European Peptide Society 2: 66-72.
26. Chua BY, Zeng W, Lau YF, Jackson DC, (2007) Comparison of lipopeptide-based immunocontraceptive vaccines containing different lipid groups. Vaccine 25: 92-101.
27. Chua BY, Eriksson EM, Poole DP, Zeng W, Jackson DC, (2008) Dendritic cell acquisition of epitope cargo mediated by simple cationic peptide structures. Peptides 29: 881-890.
28. Firat H, Garcia-Pons F, Tourdot S, Pascolo S, Scardino A, et al. (1999) H-2 class I knockout, HLA-A2.1-transgenic mice: a versatile animal model for preclinical evaluation of antitumor immunotherapeutic strategies. European journal of immunology 29: 3112-3121.
29. Lindblad EB, (2004) Aluminium compounds for use in vaccines. Immunology and cell biology 82: 497-505.
30. Pileri P, Uematsu Y, Campagnoli S, Galli G, Falugi F, et al. (1998) Binding of hepatitis C virus to CD81. Science 282: 938-941.
31. Munoz N, Manalastas R Jr, Pitisuttithum P, Tresukosol D, Monsonego J, et al. (2009) Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial. Lancet 373: 1949-1957.
32. Buonaguro L, Tagliamonte M, Tornesello ML, Buonaguro FM, (2011) Developments in virus-like particle-based vaccines for infectious diseases and cancer. Expert review of vaccines 10: 1569-1583.
33. Liu YV, Massare MJ, Barnard DL, Kort T, Nathan M, et al. (2011) Chimeric severe acute respiratory syndrome coronavirus (SARS-CoV) S glycoprotein and influenza matrix 1 efficiently form virus-like particles (VLPs) that protect mice against challenge with SARS-CoV. Vaccine 29: 6606-6613.
34. Middelberg AP, Rivera-Hernandez T, Wibowo N, Lua LH, Fan Y, et al. (2011) A microbial platform for rapid and low-cost virus-like particle and capsomere vaccines. Vaccine 29: 7154-7162.
35. Walpita P, Barr J, Sherman M, Basler CF, Wang L, (2011) Vaccine potential of Nipah virus-like particles. PloS one 6: e18437.
36. Jagu S, Kwak K, Garcea RL, Roden RB, (2010) Vaccination with multimeric L2 fusion protein and L1 VLP or capsomeres to broaden protection against HPV infection. Vaccine 28: 4478-4486.
37. Lu B, Huang Y, Huang L, Li B, Zheng Z, et al. (2010) Effect of mucosal and systemic immunization with virus-like particles of severe acute respiratory syndrome coronavirus in mice. Immunology 130: 254-261.
38. Buonaguro L, Devito C, Tornesello ML, Schroder U, Wahren B, et al. (2007) DNA-VLP prime-boost intra-nasal immunization induces cellular and humoral anti-HIV-1 systemic and mucosal immunity with cross-clade neutralizing activity. Vaccine 25: 5968-5977.
39. Visciano ML, Tagliamonte M, Tornesello ML, Buonaguro FM, Buonaguro L, (2012) Effects of adjuvants on IgG subclasses elicited by Virus-Like Particles. Journal of translational medicine 10: 4.
40. Velasquez LS, Hjelm BE, Arntzen CJ, Herbst-Kralovetz MM, (2010) An intranasally delivered Toll-like receptor 7 agonist elicits robust systemic and mucosal responses to Norwalk virus-like particles. Clinical and vaccine immunology: CVI 17: 1850-1858.
41. Schneider-Ohrum K, Giles BM, Weirback HK, Williams BL, DeAlmeida DR, et al. (2011) Adjuvants that stimulate TLR3 or NLPR3 pathways enhance the efficiency of influenza virus-like particle vaccines in aged mice. Vaccine 29: 9081-9092.
42. Wang BZ, Xu R, Quan FS, Kang SM, Wang L, et al. (2010) Intranasal immunization with influenza VLPs incorporating membrane-anchored flagellin induces strong heterosubtypic protection. PloS one 5: e13972.
43. Eriksson M, Andreasson K, Weidmann J, Lundberg K, Tegerstedt K, et al. (2011) Murine polyomavirus virus-like particles carrying full-length human PSA protect BALB/c mice from outgrowth of a PSA expressing tumor. PloS one 6: e23828.
44. Jackson DC, Lau YF, Le T, Suhrbier A, Deliyannis G, et al. (2004) A totally synthetic vaccine of generic structure that targets Toll-like receptor 2 on dendritic cells and promotes antibody or cytotoxic T cell responses. Proc Natl Acad Sci U S A 101: 15440-15445.
45. Alphs HH, Gambhira R, Karanam B, Roberts JN, Jagu S, et al. (2008) Protection against heterologous human papillomavirus challenge by a synthetic lipopeptide vaccine containing a broadly cross-neutralizing epitope of L2. Proc Natl Acad Sci U S A 105: 5850-5855.
46. Deliyannis G, Kedzierska K, Lau YF, Zeng W, Turner SJ, et al. (2006) Intranasal lipopeptide primes lung-resident memory CD8+ T cells for long-term pulmonary protection against influenza. Eur J Immunol 36: 770-778.
47. Torresi J, Stock OM, Fischer AE, Grollo L, Drummer H, et al. (2007) A self-adjuvanting multiepitope immunogen that induces a broadly cross-reactive antibody to hepatitis C virus. Hepatology 45: 911-920.